This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called Marstacimab for people with a condition known as hemophilia. Hemophilia is a rare bleeding disorder where blood doesn’t clot properly, leading to excessive bleeding. The study includes individuals with severe hemophilia A or moderately severe to severe hemophilia B, with or without inhibitors. Inhibitors are substances that can interfere with the treatment of hemophilia, making it more challenging to manage the condition.
The purpose of this study is to evaluate how safe and tolerable Marstacimab is when used over a long period. Participants will receive the treatment as a solution for injection, either in a pre-filled pen or syringe, which is administered under the skin. The study will monitor participants for any side effects, including reactions at the injection site, changes in vital signs, and any significant changes in laboratory test results. The study will also track the number of bleeding episodes and any changes in joint health over time.
Participants in this study will be observed for several years to gather comprehensive data on the treatment’s impact. The study aims to provide valuable insights into the long-term management of hemophilia using Marstacimab, helping to improve the quality of life for those affected by this condition. The study is open-label, meaning both the researchers and participants know what treatment is being administered, and it is an extension of previous studies, allowing for continued observation and data collection.
Austria 
Croatia 
Czechia 
Denmark 
France 
Germany 
Italy 
Slovakia 
Spain 
